Pharmafile Logo

transcreation

- PMLiVE

FDA Fast Track designation given to Enterome’s follicular lymphoma treatment

Follicular lymphoma, a type of non-Hodgkin’s lymphoma, has few initial symptoms

- PMLiVE

Medicus Pharma recruits first patient in cancer patch trial

The first patient has been dosed as part of a phase 2 trial in the UAE

Genesis giveaway of a minifigure

Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212

Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10...

Genesis Research Group

- PMLiVE

What to expect from Obesity Week 2025: Key trends shaping the future of obesity care

Discover how Inizio experts are shaping the future of obesity care—where science, strategy, and innovation unite to advance cardiometabolic health and drive real-world impact.

Inizio

- PMLiVE

AI with intent: How Inizio is redefining pharma through precision and partnership

At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact—discover how this human-centered innovation is defining the...

Inizio

- PMLiVE

GSK’s Blenrep approved by FDA for multiple myeloma

Approval supported by positive results from phase 3 trial

- PMLiVE

Medherant announces positive phase 1 results for testosterone patch for women

University of Warwick spin-out develops first-in-class testosterone patch to support women through menopause

- PMLiVE

Lilly to invest $1.2bn in Puerto Rico manufacturing site

The investment will strengthen Lilly’s US manufacturing network

- PMLiVE

Doctored Truths urges pharma to lead the fight against health misinformation

“Doctored Truths” exposes the escalating crisis of health misinformation and disinformation, which has been ranked the world’s top short-term risk to the world, for the second year in a row....

Havas Lynx

- PMLiVE

Novartis presents new positive data for rheumatic autoimmune disease treatment

Patient outcome benefits were observed in two ongoing phase 3 trials

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links